MedTrace Logo

Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI

NCT04359732 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2026-02-06

No results posted yet for this study

Summary

Evaluate the potential role of PET/MRI as a predictor of esophageal and junctional cancers in response to neoadjuvant chemoradiotherapy (nCRT).

Conditions

  • Esophageal Cancer
  • Esophageal Neoplasms

Interventions

OTHER

hybrid PET/MRI

An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.

Sponsors & Collaborators

  • Associazione Italiana per la Ricerca sul Cancro

    collaborator OTHER

  • IRCCS San Raffaele

    lead OTHER

Principal Investigators

  • Francesco De Cobelli, MD · IRCCS Ospedale San Raffaele

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2026-02-02
Completion
2026-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04359732 on ClinicalTrials.gov